◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Alkem Laboratories Limited (ALKEM)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-09-20
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally.
关键数据
- 市值: ₹654 billion
- 收入（截至 2026-03-31 财年）: ₹145.3B
- 净利润: ₹23.0B
- 毛利率: 64.2%
- 净利率: 15.8%
查看交互式图表与完整报表 →
年度利润表
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|
| 总收入 | ₹145.3B | ₹128.0B | ₹124.4B | ₹114.4B | — |
| 毛利 | ₹93.3B | ₹79.5B | ₹74.1B | ₹64.6B | — |
| 营业利润（EBIT） | ₹26.5B | ₹21.8B | ₹19.8B | ₹13.3B | — |
| 净利 | ₹23.0B | ₹21.7B | ₹18.0B | ₹9.8B | — |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 ALKEM 交互式查看器。 /companies/us/ALKEM
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.